'dexamethasone 20mg'

COMPOSITION: Each film-coated tablet contains: Selinexor ……………………… 20mg INDICATION: LuciSelin is a nuclear export inhibitor indicated: · In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. · In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. · For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy. DOSAGE AND USE: 1 Multiple Myeloma in Combination with Bortezomib and Dexamethasone (Svd): The recommended dosage of LuciSelin is 100 mg taken orally once weekly on Day 1 of each week until disease progression or unacceptable toxicity in combination with: · Bortezomib 1.3 mg/m administered subcutaneously once weekly on Day 1 of each week for 4 weeks followed by 1 week off. · Dexamethasone 20 mg taken orally twice weekly on Days 1 and 2 of each week. 1.2 Multiple Myeloma in Combination with Dexamethasone (Sd): The recommended dosage of LuciSelin is 80 mg taken orally on Days 1 and 3 of each week until disease progression or unacceptable toxicity in combination with dexamethasone 20mg taken orally with each dose of LuciSelin on Days 1 and 3 of each week. 2 DLBCL: Recommended dosage of LuciSelin is 60 mg taken orally on Days 1 and 3 of each week. Tablet should be swallowed whole & not chewed or crushed. STORAGE: Store at or below 30°C, in a dry place. MANUFACTURED AND MARKETED BY: LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

EACH FILM-COATED LUCICABOZ TABLET CONTAINS: Cabozantinib 20mg INDICATION: LuciCaboz a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). DOSAGE AND USE: Recommended Dose: 140 mg orally, once daily. Instruct patients not to eat for at least 2 hours before and at least 1 hour after taking LuciCaboz. STORAGE: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Keep medicine out of the reach of Children. MANUFACTURED AND MARKETED BY: LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

EACH FILM-COATED LUCITRAM TABLET CONTAINS: Avatrombopag maleate 23.6mg equivalent to avatrombopag 20mg INDICATION: LuciAvat is a thrombopoietin receptor agonist indicated for the treatment of: · Thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. · Thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. DOSAGE AND USE: 1. Chronic Liver Disease: Dose LuciAvat based upon platelet count prior to procedure, orally for 5 days beginning 10 to 13 days before procedure. For platelet count less than 40 × 109/L, the dose is 60 mg (3 tablets) once daily; for platelet count 40 to less than 50 × 109/L, the dose is 40 mg (2 tablets) once daily. 2. Chronic Immune Thrombocytopenia: Initiate LuciAvat at 20 mg (1 tablet) once daily. Adjust the dose or frequency of dosing to maintain platelet count greater than or equal to 50 × 109 /L. Do not exceed 40 mg per day. Tablets should be swallowed whole & not chewed or crushed and with food. STORAGE: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Keep medicine out of the reach of Children. MANUFACTURED AND MARKETED BY: LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

COMPOSITION: Each film-coated tablet contains: Venetoclax … 100mg INDICATION: LuciVenet is a BCL-2 inhibitor indicated: · For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). · In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. DOSAGE AND USE: 5-week ramp-up dosing schedule Week 1: LuciVenet 20mg once daily Week 2: LuciVenet 50mg once daily Week 3: LuciVenet 100mg once daily Week 4: LuciVenet 200mg once daily Week 5: LuciVenet 400mg once daily The recommended dosage of LuciVenet is 400 mg once daily after completion of the 5-week ramp-up dosing schedule. Continue LuciVenet until disease progression or unacceptable toxicity. Tablet should be swallowed whole & not chewed or crushed. STORAGE: in a dry place and store at 20°C to 25°C. MANUFACTURED AND MARKETED BY: LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

COMPOSITION: Each LuciXaz capsule contains: 5.7mg lxazomib citrate equivalent to lxazomib….………4mg INDICATION: LuciXaz is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. DOSAGE AND USE: Recommended starting dose of 4 mg taken orally on Days 1, 8, and 15 of a 28-day cycle. Dose should be taken at least one hour before or at least two hours after food. Capsule should be swallowed whole & not chewed or crushed. STORAGE: in a dry place and store at 20°C to 25°C. MANUFACTURED AND MARKETED BY: LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

EACH LUCISOT TABLET CONTAINS: Sotorasib ……………… 120mg INDICATION: LuciSot is an inhibitor of the RAS GTPase family indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. DOSAGE AND USE: The recommended dosage of LuciSot is 960 mg (eight 120 mg tablets) orally once daily until disease progression or unacceptable toxicity. Take LuciSot at the same time each day with or without food. Recommended LuciSot Dose Reduction Levels for Adverse Reactions: 1. First dose reduction: 480 mg (4 tablets) once daily 2. Second dose reduction: 240 mg (2 tablets) once daily Tablets should be swallowed whole & not chewed or crushed. STORAGE: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Keep medicine out of the reach of Children. MANUFACTURED AND MARKETED BY: LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos